Montelukast inhibits hypoxia inducible factor-1 α translation in prostate cancer cells.

In conclusion, we identify montelukast may be used as a novel agent for the treatment of prostate cancer by decreasing HIF-1α protein translation.
PMID: 29708817 [PubMed - as supplied by publisher]

Source: Cancer Biology and Therapy - April 30, 2018 Category: Cancer & Oncology Authors: Tang C, Lei H, Zhang J, Liu M, Jin, Luo H, Xu H, Wu Y Tags: Cancer Biol Ther Source Type: research